Gadolinium-based contrast agent accelerates the migration of astrocyte via integrin αvβ3 signaling pathway

Sci Rep. 2022 Apr 7;12(1):5850. doi: 10.1038/s41598-022-09882-7.

Abstract

Gadolinium (Gd)-based contrast agents (GBCAs) are chemicals injected intravenously during magnetic resonance imaging to enhance the diagnostic yield. Repeated use of GBCAs causes their deposition in the brain. Such deposition may affect various neuronal cells, including astrocytes. In this study, we examined the effect of GBCAs (Omniscan, Magnescope, Magnevist, and Gadovist) on astrocyte migration, which is critical for formation of neurons during development and maintaining brain homeostasis. All GBCAs increased cell migration and adhesion with increased actin remodelling. Knockdown of integrin αvβ3 by RNAi or exposure to integrin αvβ3 inhibitor reduced astrocyte migration. GBCAs increased phosphorylation of downstream factors of αvβ3, such as FAK, ERK1/2, and Akt. The phosphorylation of all these factors were reduced by RNAi or integrin αvβ3 inhibitor. GBCAs also increased the phosphorylation of their downstream factor, Rac1/cdc42, belonging to the RhoGTPases family. Coexposure to the selective RhoGTPases inhibitors, decreased the effects of GBCAs on cell migration. These findings indicate that GBCAs exert their action via integrin αvβ3 to activate the signaling pathway, resulting in increased astrocyte migration. Thus, the findings of the study suggest that it is important to avoid the repeated use of GBCAs to prevent adverse side effects in the brain, particularly during development.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Astrocytes
  • Contrast Media* / pharmacology
  • Gadolinium* / pharmacology
  • Integrin alphaVbeta3
  • Magnetic Resonance Imaging / methods
  • Signal Transduction

Substances

  • Contrast Media
  • Integrin alphaVbeta3
  • Gadolinium